Introduction
============

Colorectal cancer (CRC) is the third most common malignancy and one of the leading causes of cancer-associated mortality worldwide ([@b1-mmr-18-06-5361]). For tumor molecular profiling of CRC, several organizations have completed large-scale sequencing projects, including The Cancer Genome Atlas (TCGA) ([@b2-mmr-18-06-5361]), Dana-Farber Cancer Institute (DFCI) ([@b3-mmr-18-06-5361]), Memorial Sloan Kettering Cancer Center ([@b4-mmr-18-06-5361]) and Genentech, Inc. ([@b5-mmr-18-06-5361]). Exome-wide sequencing has identified recurrent gene mutations and dysregulated signaling pathways that may contribute to carcinogenesis, including *APC, WNT signaling pathway regulator* (*APC*), *tumor protein p53* (*TP53*), *KRAS proto-oncogene, GTPase* (*KRAS*) and *titin* (*TTN*) genes, and the WNT, tumor growth factor-β, phosphoinositide 3-kinase and P53 signaling pathways ([@b2-mmr-18-06-5361]). TCGA has detailed subgroups of tumors characterized by hypermutation (16%), or by a high degree of microsatellite instability (MSI-H) and non-hypermutated (84%). Together with clinical annotations, these molecular profiling methods can be used to identify potentially actionable tumor biomarkers that may be useful for clinical practice.

Over the past decades, the 5-year relative survival rate of patients with CRC has increased markedly ([@b6-mmr-18-06-5361]). In China, \~376,000 people are diagnosed with CRC per year, which is 2.5 times higher than in the United States ([@b7-mmr-18-06-5361],[@b8-mmr-18-06-5361]). Additionally, 5-year relative survival is substantially lower in China (\~47.2%) compared with in the United States (\~66%) ([@b9-mmr-18-06-5361]). In China, survival of patients with CRC in urban areas, including Shanghai, is markedly higher than in rural areas, due to differences in socioeconomics and healthcare standards ([@b9-mmr-18-06-5361]). Next-generation sequencing enables precision medicine, the tailoring of treatments based on unique genomic variations of each patient\'s tumor. Sequencing a panel of CRC-associated genes may identify actionable genomic driver mutations and further determine mutational burden in CRC, which is more cost effective, efficient and achieves higher sequencing depth than whole-exome sequencing. CRC panel design is mainly based on the TCGA database. Sequencing data generated from TCGA ([@b2-mmr-18-06-5361]) or previous studies ([@b3-mmr-18-06-5361]--[@b5-mmr-18-06-5361]) are essential sources, but tumors from Asian populations have not been the subject of comprehensive evaluation. Furthermore, in the previous studies ([@b10-mmr-18-06-5361]--[@b13-mmr-18-06-5361]) almost all exome-wide sequencing in CRC, including whole-exome sequencing and target sequencing, were limited to the detection of single nucleotide variations (SNVs) and small insertion and deletions (InDels) in genes. While structure variations, including copy number variation (CNV) and chromosomal rearrangement, are also key factors in the process of cancer development.

In the present study, 10 CRC patients were recruited at the Shanghai Tenth People\'s Hospital (Shanghai, China) as a representative sample of CRC patients in the Shanghai Han population and Chinese urban population. The whole genomes of the 10 CRC patient tumors and matched normal tissues were sequenced. A comprehensive analysis was performed, including identification of SNVs, InDels, CNVs and chromosomal rearrangement, which not only validated results from TCGA to a certain extent, but also resulted in novel findings.

Patients and methods
====================

### Patients and samples

Fresh primary colorectal tumor tissues and matched adjacent normal tissues were collected from 10 patients with pathologically confirmed CRC at the Shanghai Tenth People\'s Hospital Affiliated to Tongji University between March and May 2015. Patient clinical characteristics are presented in [Table I](#tI-mmr-18-06-5361){ref-type="table"}. Patients were numbered CRC-1 to 10. The median age was 62 years (range, 43--82 years), 6 cases were female, 8 cases exhibited colon cancer and 2 were rectal cancer. No patients had received therapeutic procedures, including chemotherapy or radiotherapy. Samples were frozen immediately in liquid nitrogen and stored at −80°C prior to analysis.

### DNA extraction

DNA was extracted from fresh frozen tissue using QIAamp DNA Minikit (Qiagen GmbH, Hilden, Germany) according to the manufacturers\' protocol. DNA was quantified using the Qubit Fluorometer (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA).

### Library preparation

A total of 0.5 µg DNA per sample was used as input material for the DNA library preparations. A sequencing library was generated using Truseq Nano DNA HT Sample Prep kit (Illumina, Inc., San Diego, CA, USA) following the manufacturer\'s recommendations and index codes were added to each sample. Briefly, genomic DNA samples were fragmented by sonication to a size of \~350 bp (duty factor 10%, peak incident power 175, cycles per burst 200, treatment time 180 seconds, bath temperature 4--8°C). Then, DNA fragments were end polished, A-tailed and ligated with the full-length adapter for Illumina sequencing, followed by further polymerase chain reaction (PCR) amplification using KAPA HiFi HotStart ReadyMix (Kapa Biosystems, Inc., Wilmington, MA, USA). Primers are based on the P5 and P7 Illumina flow cell sequences, and are suitable for the amplification of libraries prepared with full-length adapters (P5: 5′-AATGATACGGCGACCACCGAGATC-3′, P7: 5′-CAAGCAGAAGACGGCATACGA-3′). Thermocycling conditions: Initial denaturation 98°C for 45 sec, denaturation 98°C for 15 sec, annealing 60°C for 30 sec, extension 72°C for 30 sec, library amplification with 3 cycles and final extension 72°C for 1 min, hold at 4°C. Subsequently, PCR products were purified by the AMPure XP system (Beckman Coulter, Inc., Brea, CA, USA), libraries were analyzed for size distribution by Agilent2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA) and quantified by quantitative PCR (3 nM) using KAPA Library Quantification kits (Kapa Biosystems, Inc.) according to the manufacturer\'s protocol. The primers were the same as for the amplification procedure (P5: 5′-AATGATACGGCGACCACCGAGATC-3′, P7: 5′-CAAGCAGAAGACGGCATACGA-3′). qPCR protocol for library quantification consists of an initial denaturation step at 95°C for 5 min followed by 35 cycles of denaturation at 95°C for 30 sec and combined annealing/extension at 60°C for 45 sec. A total of 6 pre-diluted DNA Standards and appropriately diluted NGS libraries are amplified at the same time. The average Cq value for each DNA standard was plotted against its known concentration to generate a standard curve. The standard curve is used to convert the average Cq values for diluted libraries to concentration, from which the working concentration of each library is calculated.

### Clustering and sequencing

The clustering of the index-coded samples was performed on a cBot Cluster Generation System using HiseqX PE Cluster kit V2.5 (Illumina, Inc.) according to the manufacturer\'s protocol. Following cluster generation, the DNA libraries were sequenced using the IlluminaHiseq platform and 150 bp paired-end reads were generated.

### Bioinformatics analysis

For whole-genome sequencing, clean data was obtained following filtering adapter, low quality reads and reads with proportion of N\>10%. Reads were aligned to the reference human genome (UCSC hg19; <http://genome.ucsc.edu/>) ([@b14-mmr-18-06-5361]) using the Burrows-Wheeler Aligner v. 0.7.12 ([@b15-mmr-18-06-5361]). Next, the Picard and Genome Analysis Toolkit (GATK v.3.2) ([@b16-mmr-18-06-5361]) method was adopted for duplicate removal, local realignment and Base Quality Score Recalibration, and generated quality statistics, including mapped reads, mean mapping quality and mean coverage. Finally, the GATK HaplotypeCaller was used for SNV and InDel identification.

Variants were annotated using the ANNOVAR software tool ([@b17-mmr-18-06-5361]). Annotations for mutation function (including frameshift insertion/deletion, non-frameshift insertion/deletion, synonymous SNV, nonsynonymous SNV and stopgain stoploss), mutation location \[including exonic, intronic, splicing, upstream, downstream, 3′untranslated region (UTR) and 5′UTR\], amino acid changes, 1000 Genomes Project data and dbSNP reference number were performed.

Somatic SNVs and InDels of tumors compared with matched normal tissue were named and functionally annotated using MuTect v. 1.1.4 ([@b16-mmr-18-06-5361]) and Varscan2 v. 2.3.9 ([@b18-mmr-18-06-5361]) software. Somatic mutations in coding regions were filtered (Frame_Shift_Del, Frame_Shift_Ins, In_Frame_Del, In_Frame_Ins, Missense_Mutation, Nonsense_Mutation and Nonstop_Mutation) along with challenging regions (3′Flank, 3′UTR, 5′Flank, 5′UTR, intergenic region, Splice_Site, Translation_Start_Site, RNA, Splice_Site, Translation_Start_Site). The mutations with variant allele frequency \>5% were defined as high confidence mutations. MutSigCV v.0.9 ([@b19-mmr-18-06-5361]) was used to identify significantly mutated genes (q≤0.1). Then, gene mutation data were downloaded from TCGA database (<https://tcga-data.nci.nih.gov/docs/publications/coadread_2012/>) ([@b2-mmr-18-06-5361]) and comparative analysis was performed using the sequencing data produced in the present study.

Control-FREEC v.8.7 ([@b20-mmr-18-06-5361]) software was used for identifying and annotating CNVs, including gain, loss or copy neutral loss of heterozygosity. Structural variations, including inversion, intra-chromosomal translocation and inter-chromosomal translocation, were identified using Factera ([@b21-mmr-18-06-5361]) software.

The mutation landscape across a cohort, including SNVs, InDels and mutational burden, were created by Genomic Visualizations in R (GenVisR) ([@b22-mmr-18-06-5361]). The custom mutation lists of proteins were visualized by MutationMapper tool from cBioPortal (<http://www.cbioportal.org/mutation_mapper.jsp>) and structural variants, and copy number data were visualized using CIRCOS version 0.69 (<http://www.circos.ca/>) ([@b23-mmr-18-06-5361]). Gene ontology (GO: <http://www.geneontology.org/>) and Kyoto Encyclopedia of Genes and Genomes (KEGG: <http://www.kegg.jp/>) enrichment analysis was performed to investigate the biological importance of the somatic mutated genes using the ClusterProfiler in R software (10.18129/B9.bioc.clusterProfiler).

Results
=======

### Clinical and sequencing data

The 10 CRC samples were analyzed ([Table I](#tI-mmr-18-06-5361){ref-type="table"}). The microsatellite instability status of the CRC-9 tumor was high (MSI-H), the CRC-7 tumor was low (MSI-L) and others were microsatellite stable.

Whole-genome sequencing achieved an average of 27.8× coverage of the tumor genomes and 27.9× coverage of the germline genome ([Table II](#tII-mmr-18-06-5361){ref-type="table"}). Somatic DNA alterations were analyzed, including SNVs, InDels, CNVs and chromosomal rearrangements. An overall mutation rate of \~7.78 per Mb with a range of 2.11--29.79 mutations per Mb was calculated ([Table II](#tII-mmr-18-06-5361){ref-type="table"}; [Fig. 1A](#f1-mmr-18-06-5361){ref-type="fig"}). In study of TCGA ([@b2-mmr-18-06-5361]), cases with mutation rates \>12 per Mb were designated as hypermutated. The mutation rate of CRC-9 was 29.79 per Mb in the present study, which was the only hypermutated case ([Fig. 1A](#f1-mmr-18-06-5361){ref-type="fig"}).

### Significantly mutated somatic genes

The MutSigCV tool was used to define significantly mutated genes and identified 32 significantly mutated genes ([Fig. 1B](#f1-mmr-18-06-5361){ref-type="fig"}). [Fig. 1](#f1-mmr-18-06-5361){ref-type="fig"} presents the significantly mutated genes ([Fig. 1B](#f1-mmr-18-06-5361){ref-type="fig"}), mutation type ([Fig. 1B](#f1-mmr-18-06-5361){ref-type="fig"}), frequency and tumor mutation burden ([Fig. 1A](#f1-mmr-18-06-5361){ref-type="fig"}). The five most frequently mutated genes were *TP53* (4/10), transmembrane protein 128 (*TMEM128*; 4/10), *KRAS* (4/10), *FAM47C* (4/10) and BAGE family member 2 (*BAGE2*; 4/10).

The mutation frequency of the 32 significantly mutated genes was compared with TCGA data ([Fig. 1C](#f1-mmr-18-06-5361){ref-type="fig"}). Of these 32 genes, 13 were detected by TCGA, including *TP53, KRAS, FAM47C, MUC7, SHC adaptor protein 4, keratin associated protein 5--5 (KRTAP5-5), AKT serine/threonine kinase 1, taste 2 receptor member 10* (*TAS2R10*), *β-2-microglobulin* (*B2M*), *potassium voltage-gated channel interacting protein 2* (*KCNIP2*), cluster of differentiation (*CD)58, FK506 binding protein 3 (FKBP3)* and *INO80 complex subunit E* (*INO80E*; [Fig. 1C](#f1-mmr-18-06-5361){ref-type="fig"}). Among these 13 genes, the top three genes with the highest mutation frequency in the present study and TCGA data were *TP53, KRAS* and *FAM47C* (4/10). As expected, the mutated *KRAS* gene had oncogenic codon 12 mutations (3/10 samples; [Fig. 2A](#f2-mmr-18-06-5361){ref-type="fig"}) and another mutation was in codon 146 of *KRAS* (1/10 samples; [Fig. 2A](#f2-mmr-18-06-5361){ref-type="fig"}), which was in accordance with a previous study of CRC in the Chinese population ([@b24-mmr-18-06-5361]). *FAM47C* was mutated in 4 out of 10 tumor samples including 4 missense mutations (p.Q225E, p.P502P, p.Q225E and p.R701H), 1 silent mutation (p.P502P) and 1 mutation in the 3′flank region, as presented in [Fig. 2B](#f2-mmr-18-06-5361){ref-type="fig"}. The mutation frequency of *FAM47C* in the COSMIC and TCGA databases was 5.71 and 5.41%, respectively ([@b2-mmr-18-06-5361]). *FAM47C* encodes a product belonging to a family of proteins with unknown function. Additionally, *FAM47C* was mutated exclusively in *KRAS* wild-type tumors. Specific ones out of the 13 genes were mutated only in the tumor from patient CRC-9, including *TAS2R10, B2M, KCNIP2, CD58* and *INO80E*. *B2M* had two mutations (a frame shift deletion and an insertion in 3′flank region) in the CRC-9 tumor. Previous studies reported *B2M* mutations in CRC and melanoma resulting in loss of expression of HLA class 1 complexes ([@b25-mmr-18-06-5361]), suggesting these mutations benefit tumor growth by reducing antigen presentation to the immune system ([@b26-mmr-18-06-5361]). *CD58* is reported to be a surface marker that promotes self-renewal of tumor-initiating cells in CRC ([@b27-mmr-18-06-5361]).

Of the 32 significantly mutated genes, 19 were not listed in TCGA data, including *BAGE2, TMEM128, spermatogenesis associated 3* (*SPATA3*), *CD1B, RAB40A like, cysteine rich protein 3* (*CRIP3*), *crystallin* β *B2, EBP like, guanidinoacetate N-methyltransferase, hes family bHLH transcription factor 3, olfactory receptor family 2 subfamily A member 7, proline rich nuclear receptor coactivator 2, small proline rich protein 2B (SPRR2B), sushi repeat containing protein X-linked 2 (SRPX2), translocase of inner mitochondrial membrane 17A (TIMM17A), TMEM179, vesicle associated membrane protein 8 (VAMP8), WD repeat domain 61 (WDR61) and zinc finger protein 124 (ZNF124)*. Notably, CRIP3 demonstrated a nonstop_mutation (p.\*205Rext\*51) and CD1B had a nonsense_mutation (p.Q221\*) in the CRC-9 tumor, which was the hypermutated case (29.79 mutations per Mb).

Considering all somatic mutations in coding regions, the top 11 most frequently mutated genes were *mucin 4* (*MUC4*; 8/10), *immunoglobulin-like and fibronectin type III domain containing 1* (*IGFN1*; 5/10), *ALMS1, centrosome and basal body associated protein* (4/10), *APC* (4/10), *family with sequence similarity 47 member C* (*FAM47C*; 4/10), *KRAS* (4/10), *mucin like 3* (*DPCR1;* 3/10), *family with sequence similarity 186 member A* (*FAM186A*; 3/10), *polycystin 1, transient receptor potential channel interacting* (3/10), and *TTN* (3/10). The most frequent mutated gene was *MUC4* (8/10), with a mutation frequency that was higher compared with that reported in a previous study ([@b2-mmr-18-06-5361]). The mutation frequency of *MUC4* has been previously reported as 9.72% (Genentech) ([@b5-mmr-18-06-5361]), 5.33% (DFCI) ([@b3-mmr-18-06-5361]) and 2.23% (TCGA) ([@b2-mmr-18-06-5361]). MUC4 is a major constituent of mucus that has important roles in the protection of epithelial cells and has been implicated in epithelial renewal and differentiation. The mucin gene *MUC4* is reported to be a transcriptional and post-transcriptional target of the oncogene *KRAS* in pancreatic cancer ([@b28-mmr-18-06-5361]). However, *MUC4* was not defined as a driver gene by MutSigCV in the current study, which may due to the positions of *MUC4* mutations, which were not in functional regions ([Fig. 2C](#f2-mmr-18-06-5361){ref-type="fig"}).

### Functional enrichment analysis of mutated genes

To better understand the biological function of mutated genes, GO and KEGG enrichment analysis were performed. All mutated genes were categorized into 16 functional categories by GO enrichment (adjusted P\<0.05; [Table III](#tIII-mmr-18-06-5361){ref-type="table"}). Notably, 11 functional categories were associated with transporter/channel activity. House *et al* ([@b29-mmr-18-06-5361]) reported that voltage-gated Na^+^ channel activity increases colon cancer transcriptional activity and invasion via persistent mitogen-activated protein kinase signaling. All mutated genes were categorized into three pathways by KEGG enrichment, including 'neuroactive ligand-receptor interaction', 'alanine, aspartate and glutamate metabolism' and 'nicotine addiction' (adjusted P\<0.05).

### Chromosomal rearrangement

Chromosomal structural variation (SV) was also analyzed using whole-genome sequencing of 10 tumors with matched normal samples. There were 21 candidate-chromosomal rearrangements detected by filtering criterion of above 20 supporting reads, including 2 inversions and 19 translocations ([Table IV](#tIV-mmr-18-06-5361){ref-type="table"}). Among these, the fusion sites of 4 SVs were in gene regions, which were termed fusion genes, including, *EF-hand domain family member B-mannosidase α* class 1A member 1, phosphorylase kinase regulatory subunit β (*PHKB*)-*NOTCH2* (2 samples) and *polyamine modulated factor 1-FAM182B*. A fusion of *PHKB* and *NOTCH2* was identified in 2 out of 10 CRCs and the fusion occurred downstream of *PHKB* exon 5 and upstream of *NOTCH2* exon 4 ([Fig. 3A](#f3-mmr-18-06-5361){ref-type="fig"}). This appears likely to enable translation of the fusion protein (the glycosyl hydrolases family 15 domain of PHKβ linked with the calcium-binding epidermal growth factor-like domain of Notch2; [Fig. 3A](#f3-mmr-18-06-5361){ref-type="fig"}). *PHKB* encodes a member of the PHKβ regulatory subunit family. *PHKB* was reported to promote glycogen breakdown and cancer cell survival by interacting with cell migration inducing hyaluronidase 1 ([@b30-mmr-18-06-5361]). *NOTCH2* encodes a member of the Notch family with a role in a variety of developmental processes by controlling cell fate decisions. Previous studies reported that Notch2 is a crucial regulator of self-renewal and tumorigenicity in human hepatocellular carcinoma cells ([@b31-mmr-18-06-5361],[@b32-mmr-18-06-5361]) and contributes to cell growth, invasion and migration in salivary adenoid cystic carcinoma ([@b33-mmr-18-06-5361]).

### Copy number variations

Somatic CNVs in the 10 tumor tissues were analyzed using Control-FREEC software. Chromosomes 8 and 20 were amplified in CRC-4, and chromosome 20 was amplified in CRC-7 ([Fig. 3B](#f3-mmr-18-06-5361){ref-type="fig"}). *GNAScomplex locus* (*GNAS*) was detected in 2 out of 10 tumors (CRC-4 and CRC-7) and the *GNAS* copy number was 3. *GNAS* is located at 20q13.32. A previous study reported that amplification of the *GNAS* locus may contribute to the pathogenesis of breast cancer ([@b34-mmr-18-06-5361]). In TCGA, *GNAS* was amplified in 8.17% tumor samples ([@b2-mmr-18-06-5361]). In the CRC-7 tumor, a subset of genes located at chromosome 20 was amplified (copy number 3), including teashirt zinc finger homeobox 2, aurora kinase A, GNAS, SS18L1 nBAF chromatin remodeling complex subunit, regulator of telomere elongation helicase 1 and ADP ribosylation factor related protein 1. SVs of 10 tumors are presented in [Fig. 3C](#f3-mmr-18-06-5361){ref-type="fig"}, including chromosomal rearrangements and CNVs, displayed as CIRCOS plots.

Discussion
==========

In the present study, whole-genome sequencing was performed on tumor and matched adjacent normal tissues from 10 patients with CRC in Shanghai. A comprehensive analysis including SNVs, InDels, CNVs and chromosomal rearrangements was performed, which identified certain recurrent and novel variations in CRC patients from the Han population in Shanghai, eastern China.

Among the significantly mutated genes, certain previously reported driver genes in CRC were identified, including *TP53, KRAS, FAM47C* and *MUC7*. Additionally, a group of driver genes were identified that have rarely been reported in CRC, including *BAGE2, TMEM128, SPATA3 and CD1B*. Certain well-established mutated genes, including *APC* and *TTN*, which were defined as driver genes in a previous study ([@b2-mmr-18-06-5361]), were not significantly mutated genes in the present study. Signaling pathway analysis indicated that the mutated genes may alter pathways associated with channel activity. Notably, *PHKB-NOTCH2* fusion was detected in 2 out of 10 tumors, which has not been previously reported in CRC, to the best of our knowledge. The structure of fusion proteins was also predicted. Although, further study will be required to fully understand the role of *PHKB-NOTCH2* fusion.

The tumor mutation burden of the tumor of CRC-9 was 29.79 per Mb, which indicates hypermutation according to TCGA ([@b2-mmr-18-06-5361]). TCGA identified 16% of CRCs to be hypermutated, three quarters of which are due to a mismatch repair defect phenotype, otherwise known as MSI-H. In CRC-9, 23 significantly mutated genes were identified, while the other 9 cases harbored a mean of 3.3 significantly mutated genes (range, 3--4). Somatic mutations have the potential to encode 'non-self' immunogenic antigens. Evidence demonstrated improved responses to programmed cell death protein 1 (PD-1) blockade in CRC with MSI-H ([@b35-mmr-18-06-5361],[@b36-mmr-18-06-5361]). The tumor of patient CRC-9 was a locally advanced colon cancer (T4bN0M0) with poor-moderate differentiation and MSI-H. Cancer antigen (CA)12-5 and CA15-3 were at high levels following surgery, which indicated a high risk of recurrence. CRC-9 may benefit from PD-1 blockade to treat recurrence.

There are large differences in diet, living conditions and genetic background between the Han population and ethnic minorities, which are associated with CRC risk. For example, the Uyghur population in Xinjiang is predominantly Caucasian, while the Han population is mainly Mongoloid. Uyghur CRC patients have a lower age of onset, larger tumor size, more advanced stage and higher proportion of signet-ring cell carcinoma and mucinous adenocarcinoma compared with Han patients ([@b37-mmr-18-06-5361]). A previous study reported that CRC patients in the Uyghur population exhibited a higher rate of *KRAS* mutation compared with the Han population (46.2% vs. 28.8%) and the mutation rate in *KRAS* codon 12 is higher in the Uygur population than in the Han population (38.5% vs. 17.3%) ([@b38-mmr-18-06-5361]). In the present study, the *KRAS* mutation rate was 4/10 and 3/10 of mutations were in codon 12, which was at a comparable level to the Uyghur population ([@b38-mmr-18-06-5361]).

There are limitations in this study. Firstly, the sample size was small, which lead to low statistical power to identify significantly mutated genes and could not well represent Chinese Han population. Secondly, the sequencing depth was not high enough to detect mutations with low variant allele frequency. Thirdly, further validation in samples and functional studies were not performed. Finally, due to the short time from patient enrollment, survival analysis was not performed. In future studies of a panel of CRC-associated genes, including reported recurrent genes and novel mutated genes in the present study, will be analyzed in a cohort of patients with CRC. In addition, survival analysis with genomic variations should be performed following long term follow-up for CRC patients.

In conclusion, in the present study, reported mutated genes were validated to a certain extent and novel mutations were identified, including fusion gene *PHKB-NOTCH2*. In addition, mutated genes were enriched in functions associated with channel activity, which has rarely been reported by previous CRC studies ([@b2-mmr-18-06-5361],[@b4-mmr-18-06-5361]). The present study produced a CRC genomic mutation profile, which provides a valuable resource for further insight into CRC within the eastern Chinese Han population.
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![Chromosomal structural rearrangements and copy number variations in the ten colorectal tumors. (A) A schematic of *PHKB-NOTCH2* translocation is presented for the fusion transcript and predicted fusion protein. (B) Chromosome 8 was amplified in CRC-4, and chromosome 20 was amplified in CRC-4 and CRC-7. (C) Structural variations in the ten colorectal tumors displayed as CIRCOS plots. *PHKB*, phosphorylase kinase regulatory subunit β; CRC, colorectal cancer.](MMR-18-06-5361-g02){#f3-mmr-18-06-5361}

###### 

Clinical characteristics of ten colorectal cancer patients.

  Patients   Sex      Age   Clinical diagnosis   MSI     TNM stage   Differentiation     Location           Size (cm)   Lymphatic metastasis   Distant metastasis
  ---------- -------- ----- -------------------- ------- ----------- ------------------- ------------------ ----------- ---------------------- --------------------
  CRC-1      Female   62    Colon cancer         MSS     T3N0M0      Moderately          Sigmoid colon      6×4×1       0/12                   No
  CRC-2      Female   68    Colon cancer         MSS     T3N1M0      Moderately          Right colon        7×4.5×4     1/9                    No
  CRC-3      Female   58    Rectal cancer        MSS     T4N1M0      Moderately          Rectum             4.5×3×3     1/5                    No
  CRC-4      Male     80    Colon cancer         MSS     T3N1M0      Poorly-moderately   Ascending colon    4×3×1.5     3/13                   No
  CRC-5      Male     57    Colon cancer         MSS     T1N0M0      Moderately-well     Colon              1×1.5×1     0/5                    No
  CRC-6      Female   75    Colon cancer         MSS     T4aN1M1     Moderately          Ascending colon    9.5×7×2.5   1/14                   Yes
  CRC-7      Male     82    Rectal cancer        MSI-L   T4bN0M0     Moderately          Rectum             6×5.5×1.5   0/15                   No
  CRC-8      Male     62    Colon cancer         MSS     T3N0M0      Moderately          Transverse colon   4×3.5×2     0/12                   No
  CRC-9      Female   60    Colon cancer         MSI-H   T4bN0M0     Poorly-moderately   Transverse colon   6×4.5×4     0/17                   No
  CRC-10     Female   43    Colon cancer         MSS     T1N1M0      Moderately-well     Colon              5.5×5×4     1/15                   No

MSI, microsatellite instability; MSS, microsatellite stability; MSI-L, microsatellite instability-low; MSI-H, microsatellite instability-high.

###### 

Summary of whole-genome sequencing results from each patients\' tissues.

  Patients      Tumor coverage   Normal coverage   Mutations   Mutations per Mb
  ------------- ---------------- ----------------- ----------- ------------------
  CRC-1         29.9             29.4              1092        3.64
  CRC-2         27.9             29.0              634         2.11
  CRC-3         26.9             28.2              790         2.63
  CRC-4         25.7             27.0              2180        7.27
  CRC-5         26.6             28.8              716         2.39
  CRC-6         26.7             27.2              2021        6.74
  CRC-7         29.0             25.7              3597        11.99
  CRC-8         29.9             29.1              1288        4.29
  CRC-9         27.8             27.6              8937        29.79
  CRC-10        28.1             26.6              2071        6.90
  **Average**   **27.8**         **27.9**          **2332**    **7.78**

###### 

Functional enrichment of mutated genes by GO.

  ID           Description                                                                                                       P adjust    Gene count
  ------------ ----------------------------------------------------------------------------------------------------------------- ----------- ------------
  GO:0022803   Passive transmembrane transporter activity                                                                        0.0004191   209
  GO:0015267   Channel activity                                                                                                  0.0004191   208
  GO:0022838   Substrate-specific channel activity                                                                               0.0009566   193
  GO:0001227   Transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding   0.0013711   87
  GO:0005216   Ion channel activity                                                                                              0.0015965   185
  GO:0000987   Core promoter proximal region sequence-specific DNA binding                                                       0.0118789   159
  GO:0022836   Gated channel activity                                                                                            0.0118789   144
  GO:0000982   Transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding          0.0150299   146
  GO:0001159   Core promoter proximal region DNA binding                                                                         0.0150299   159
  GO:0005267   Potassium channel activity                                                                                        0.0186798   60
  GO:0046873   Metal ion transmembrane transporter activity                                                                      0.0198865   176
  GO:0022843   Voltage-gated cation channel activity                                                                             0.0198865   65
  GO:0000978   RNA polymerase II core promoter proximal region sequence-specific DNA binding                                     0.0308052   148
  GO:0005261   Cation channel activity                                                                                           0.0330241   129
  GO:0005244   Voltage-gated ion channel activity                                                                                0.0480344   85
  GO:0022832   Voltage-gated channel activity                                                                                    0.0480344   85

###### 

Predicted chromosomal rearrangement detected by Factera.

  Sample   Type   Region1 (gene, position)   Region2 (gene, position)   Fusion sites                 
  -------- ------ -------------------------- -------------------------- --------------- ------------ ----------------------------------
  CRC-1    TRA    TMEM194B                   Intergenic                 HFM1            Intronic     chr2:191402786 to chr1:91852783
  CRC-1    TRA    ROCK1                      Intergenic                 CTD-2144E22.5   Intergenic   chr18:18519930 to chr16:35239604
  CRC-1    TRA    TRIM48                     Intergenic                 MTRNR2L9        Intergenic   chr11:55021850 to chr6:61902202
  CRC-2    INV    FAM27E3                    Intergenic                 AL445665.1      Intergenic   chr9:66971068 to chr9:69710933
  CRC-2    TRA    UNC5B                      Intergenic                 MAN1A1          Intronic     chr10:72814597 to chr6:119558701
  CRC-2    TRA    ANO3                       Intergenic                 MAN1A1          Intronic     chr11:26173964 to chr6:119558701
  CRC-2    TRA    AL445665.1                 Intergenic                 CTD-2144E22.5   Intergenic   chr9:69711250 to chr16:35239606
  CRC-2    TRA    PPAP2C                     Intergenic                 PLEKHG4B        Intergenic   chr19:249186 to chr5:15867
  CRC-3    TRA    EFHB                       Intronic                   MAN1A1          Intronic     chr3:19950145 to chr6:119558701
  CRC-3    TRA    TRIM48                     Intergenic                 MTRNR2L9        Intergenic   chr11:55021850 to chr6:61902202
  CRC-3    TRA    SOX14                      Intergenic                 ZNF92           Intergenic   chr3:137265780 to chr7:64879411
  CRC-3    TRA    PHKB                       Intronic                   NOTCH2          Intronic     chr16:47538780 to chr1:120544074
  CRC-4    INV    RP11-146D12.2              Intergenic                 CNTNAP3B        Intergenic   chr9:42416106 to chr9:44070790
  CRC-4    TRA    CSNK1G3                    Intergenic                 DLG2            Intronic     chr5:122990837 to chr11:85195011
  CRC-4    TRA    PHKB                       Intronic                   NOTCH2          Intronic     chr16:47538780 to chr1:120544074
  CRC-8    TRA    MTRNR2L1                   Intergenic                 OR4C46          Intergenic   chr17:22253139 to chr11:51568509
  CRC-8    TRA    SOX14                      Intergenic                 ZNF92           Intergenic   chr3:137265780 to chr7:64879411
  CRC-8    TRA    TRIM48                     Intergenic                 MTRNR2L9        Intergenic   chr11:55021850 to chr6:61902202
  CRC-9    TRA    PMF1                       Intronic                   FAM182B         Upstream     chr1:156186653 to chr20:26190511
  CRC-9    TRA    WDR74                      Intergenic                 PPP4R2          Intergenic   chr11:62609281 to chr3:73160133
  CRC-9    TRA    SOX14                      Intergenic                 ZNF92           Intergenic   chr3:137265780 to chr7:64879411

TRA, translocation; INV, inversion.
